Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab and Pirtobrutinib in Relapsed or Refractory Waldenstrom Macroglobulinemia
NCT07548450Phase 2Not yet recruiting
- Sponsor
- University of Utah
- Start
- Nov 2026
- Primary completion
- Nov 2034
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, pirtobrutinib in Waldenstrom macroglobulinemia (WM), sponsored by University of Utah. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mosunetuzumabpirtobrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07548450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548450.